44 results about "Cognitive regression" patented technology

A method of treating cognitive decline and / or memory deficits in a subject in need thereof includes administering to the subject a therapeutically effective amount of at least one agent that directly or indirectly increases Ptprd activity and / or decreases Aβ induced inhibition of Ptprd activity in the subject.

The invention relates to the field of radiotherapy and, more particularly, to the use of a compound based on FMS-like tyrosine kinase 3 ligand (FLT3L) and adoptive cell therapy using dendritic cells in the prevention of cognitive damage associated with radiotherapy.

Systems and methods of the present disclosure are directed to neural stimulation via audio and visual stimulations. The combination and / or sequence of audio and visual brain stimulations can adjust, control or otherwise manage the frequency of the neural oscillations to provide beneficial effects to one or more cognitive states or cognitive functions of the brain, while mitigating or preventing adverse consequences on a cognitive state or cognitive function that stems from sleep deprivation. In doing so, the present systems and methods can reduce sleep fragmentation, improve sleep quality, and slow the progression of cognitive decline in a subject with Alzheimer's disease and MCI.

Disclosed are methods for assessing severity, determining future risk, matching with a drug treatment, and measuring response to treatment, for memory dysfunction, Alzheimer's disease, and cognitive decline. Also disclosed are new methods of use for drugs and natural compounds repurposed for use in improving memory, as well as for preventing and treating memory disorders, Alzheimer's disease and cognitive decline. All the above-mentioned methods are computer assisted methods analyzing the expression of panels of genes, clinical measures, and drug databases. A universal approach in everybody, as well as a personalized approaches by gender, and by diagnosis, are disclosed.

The invention relates to the technical field of individualized cognition, in particular to an individualized cognitive decline risk prediction method and system based on multi-mode data fusion. According to the method, multi-modal longitudinal evidence-based data is integrated on the basis of a group-level pathology law, a multi-scale causal link map capable of reflecting the complete period of cognitive decline is formed, pathology time axis alignment and individualized feature normalization are achieved, the dynamic pathology process of individual specificity can be captured, and the accuracy of the pathology process is improved. By fitting individual exclusive multi-scale causal parameters and constructing a time sequence cascade digital twinborn body, forward causal simulation can be executed on multiple time scales, a cognitive decline core driving path is directly revealed, and individual risk quantification and intervention targets are generated. Detection of early hidden pathological signals, dynamic modeling of individual heterogeneity and comprehensive analysis of a multi-channel pathological mechanism are achieved, the ultra-early prediction precision of cognitive decline and individualized intervention suitability are remarkably improved, and a full-period prediction system capable of being iteratively optimized continuously is formed.

The invention provides an early biomarker for cognitive impairment of Parkinson's disease, application of the early biomarker and an intelligent analysis system for Parkinson's disease. The biomarker is a GALC gene. The intelligent analysis system for the early biomarkers of the cognitive impairment of the Parkinson's disease comprises a data integration module and a data analysis module. The data integration module is used for acquiring a gene detection result, an olfactory test score and neuroimaging data of the Parkinson's disease biomarker; and the data analysis module is used for analyzing the influence of gene variation of the Parkinson's disease biomarker on olfactory dysfunction and cognitive decline of the Parkinson's disease patient by adopting a structural equation model SEM based on the multi-modal data set. According to the application, through confluence analysis of multi-modal data, by combining genetics, neuroimaging and clinical evaluation, the rs8005172 site variation of the GALC gene is taken as an early biomarker of cognitive impairment of Parkinson's disease, so that PD patients with high cognitive decline risk can be accurately identified.

A vector for use in treating cognitive decline and / or memory deficits in a subject in need thereof includes an expression cassette that includes a nucleic acid encoding asprosin and / or an analogue thereof, operably linked to one or more regulatory elements that promote expression of the asprosin and / or an analogue thereof coding sequence, wherein the one or more regulatory elements include a nucleic acid promoter, a polyadenylation (poly(A)) tail signal, and / or posttranscriptional regulatory element.

The invention relates to the technical field of data processing, and discloses a mild cognitive impairment detection system based on multi-level data, and the system comprises a terminal device which is used for collecting physiological monitoring data, clinical narrative data and multi-modal test data of a user; the data processing module is used for performing interference identification and information purification on the multi-modal test data to generate a purified cognitive response matrix; the cognitive evaluation module is used for performing cognitive ability decoupling and group benchmarking based on the purified cognitive response matrix and outputting an individual ability level; and the closed-loop management module is used for constructing a longitudinal decline slope model based on a score sequence of individual historical multiple evaluations and carrying out risk early warning and intervention recommendation. According to the method, passive disease screening of cognitive health management is converted into an active, personalized and continuous risk monitoring and intervention process, and a powerful technical tool is provided for delaying cognitive decline.

The invention provides a quick response type nutrient composition for a cognitive load scene. The quick response type nutrient composition is prepared from the following raw materials in parts by weight: 400 to 600 parts of L-alpha-choline alfoscerate, 0.1 to 0.4 part of pyrroloquinoline quinone disodium salt, 4 to 6 parts of blueberry anthocyanin, 4 to 6 parts of gamma-aminobutyric acid, 4 to 6 parts of L-lysine and 4 to 6 parts of L-arginine. The invention further provides a preparation method and application of the quick response type nutrient composition for the cognitive load scene. Through the synergistic effect of the six components, a nerve cell energy metabolism-neurotransmitter balance-oxidation protection three-channel synergistic mechanism is formed, through the multi-target-point synergistic effect, the prepared nutrient composition has the multiple effects of improving the cognitive decline symptom, rapidly relieving cognitive fatigue, improving the thinking agility and reducing the error rate; the method is especially suitable for a high-intensity cognitive load scene. The invention belongs to the technical field of food processing.

To provide a bath agent for improving cognitive functions or preventing cognitive decline.SOLUTION: The present invention provides a bath agent for improving cognitive functions or preventing cognitive decline which contains 1,8-cineole and is foamable.SELECTED DRAWING: Figure 1

The present invention relates to treating neurodegeneration (e.g., a neurodegenerative disorder), enhancing cognitive function, delaying or reducing cognitive decline, enhancing the metabolism, and / or improving memory in patients in need thereof, e.g., patients diagnosed with a neurodegenerative disorder or displaying one or more symptoms of a neurodegenerative disorder (e.g., declining cognitive function) by administering Pla2g2f to a subject or increasing expression of Pla2g2f in a cell of a subject.

The invention provides an application of a ratio of neutrophil to lymphocyte in preparation or screening of a cognitive disorder risk diagnostic reagent. It is found that in APOE epsilon 4 allele carriers, increase of the NLR level is related to the high onset risk of cognitive impairment of the APOE epsilon 4 allele carriers, meanwhile, obesity further increases the dementia occurrence risk of high-inflammation people, and new evidence is possibly provided for synergistically promoting dementia occurrence through metabolic disorders and peripheral inflammation. In non-APOE epsilon 4 allele carriers, the high NLR level does not increase the cognitive impairment occurrence risk of old people, and it can be seen that the influence of inflammation on cognition may be an important factor for impairment of the cognitive function of the APOE epsilon 4 allele carriers. Based on an ADNI database, it is proved through longitudinal research that peripheral inflammation plays an important role in gradual decline of the cognitive function of an APOE epsilon 4 gene carrier, the high NLR level is related to fast cognitive decline, and deposition of Alzheimer's disease neuropathology markers is promoted faster. On the other hand, the AD core pathological marker plays an important role in regulating the NLR level and cognition. The invention provides a novel cognitive impairment risk diagnosis reagent and a related device which are safe, convenient, non-invasive and economical and can be widely popularized, and the reagent and the related device have great significance in improving the early recognition rate, realizing accurate intervention and optimizing treatment decision.

The disclosure relates to compositions and methods for diagnosing, stratifying, prognosing, treating and preventing and cognitive impairment, including Alzheimer's Disease, based on the identification of disease-associated metabolic transitions.

A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.

The invention discloses wearable equipment for cognitive training. The wearable equipment comprises a telephone watch which is worn by a patient so as to communicate with a specified contact person; a cognitive training module used for carrying out intervention cognitive training on a cognitive disease patient is embedded in one side of the interior of the telephone watch, and a voice assistant used for carrying out voice recognition and interaction so that the patient can carry out personalized cognitive training is embedded in the end, close to the cognitive training module, of the interior of the telephone watch. And the telephone watch, the cognitive training module and the voice assistant carry out information interaction with one another. The method has the advantages that cognitive training intervention can be continuously performed on the cognitive disease patient in daily life so as to delay the cognitive decline process and promote cognitive function rehabilitation.

The present disclosure provides methods for treating neurodegeneration or cognitive decline in a subject comprising administering an effective amount of catestatin (CST) or its equivalent to a subject afflicted with a neurodegenerative disease, thereby, reducing neurodegeneration or cognitive decline. Also disclosed are compositions comprising CST or its equivalent, suitable for use in the methods of the present disclosure.

This invention relates to the field of cognitive data processing technology, and more particularly to a method and system for physical stimulation-driven lymphatic circulation and cognitive enhancement. The system includes a physical stimulation frequency impact assessment module, a stimulation mechanical vibration analysis module, a lymphatic circulation vibration calibration module, and a stimulation frequency drive adjustment module. It utilizes pressure and temperature sensors to monitor the corresponding physical stimulation pressure and the surface temperature of the stimulated skin in real time, performing stimulation frequency impact assessment and stimulation mechanical vibration analysis to generate a physical stimulation mechanical vibration effect. It also acquires lymphatic fluid flow velocity and EEG neural activity signals, performing neurocognitive level analysis and vibration response calibration. Simultaneously, it performs lymphatic circulation cognitive regression analysis and stimulation frequency drive adjustment to generate a physical stimulation frequency drive adjustment scheme corresponding to lymphatic circulation cognitive enhancement. This invention can accurately analyze the correlation between physical stimulation and lymphatic circulation and cognitive enhancement.

The present invention relates to the field of treat age-related cognitive declines. In this study, the inventors report that GPR158, which localizes at the PC, is required for OCN- dependent autophagy induction in hippocampal neurons. Consistently, the mobilization of key autophagy players by OCN in hippocampal neurons requires core PC-proteins. In aged hippocampi, neuronal PC present an abnormal morphology, correlated with a reduction of the major core ciliary proteins levels. Conversely, restoration of their levels in aged hippocampi is sufficient to improve autophagy and cognitive deficits. Lastly, they show that core PC-proteins are required to integrate the rejuvenating effects of OCN in the hippocampus, thereby ameliorating age-related cognitive deficits. Altogether, these findings demonstrate a new paradigm for the neuron / systemic milieu communication and significantly advance our understanding of the regulatory mechanism mediating the rejuvenating effects of the pro-youth blood factor, OCN, in hippocampal neurons. This study also provides the foundation for novel therapeutic strategies to treat age-related cognitive decline, as well as neurological deficits in ciliopathies. Thus, the present invention relates to an activator of the primary cilia (PC) for use in the restoration and / or improvement of cognitive functions in a subject in need thereof.

PDE11A4 inhibitors, and methods of using the same, are provided for treating or preventing diseases or disorder associated with cognitive decline.

This invention relates to the field of cognitive testing techniques and sensor-based measurement systems to create a block design test-based visual attention and visual memory assessment system that can be used in various age groups. This system integrates testing media in the form of physical blocks, digital simulations, or a combination of both, as well as an eye-tracking data acquisition module to record gaze direction, eye movements, and attention duration in real-time during the process of observing and arranging blocks. The eye-tracking data obtained is then processed to analyze visual attention patterns, focus shifts, and their relationship to the process of remembering and arranging patterns that represent the user's visual memory ability. Unlike conventional methods that rely on subjective observations by the examiner, this system is capable of conducting objective, measurable, and data-based assessments of visual behavior.Furthermore, this system enables more efficient testing by storing results digitally for monitoring, evaluation, and research. This invention is intended to support a variety of applications, from monitoring cognitive development in children, evaluating cognitive performance in adults, to early detection of cognitive decline in the elderly.

The present disclosure relates to a method of improving cognitive function in a subject. The method includes implanting group-2 innate lymphoid cells (ILC2) in a cranium of a subject, where the ILC2 was treated with an ILC2 activator. The present disclosure further relates to a method including selecting a subject having aging-associated cognitive decline and administering to the subject an activator of innate lymphoid cell activity under conditions effective to promote innate lymphoid cell activity. The present disclosure further relates to a method of improving cognition in a subject. The method includes selecting a subject having aging-associated cognitive decline and administering to the subject a cytokine selected from the group consisting of IL-33, IL-5, IL-7, IL-25, and thymic stromal lymphopoietin.

The present application relates to the technical field of health monitoring, and discloses a home health risk assessment method and system based on night sleep activity. The present application collects night sleep physiological data and night activity trajectory data of a user through a sign monitoring module under a mattress and a night behavior trajectory module in a residence, and uploads the data after time stamp alignment by a gateway. Abnormal physiological values are cleaned out, sleep-behavior correlation features are constructed, and composite features such as difficulty falling asleep, heart rate sudden change and apnea are extracted. The risk of heart, respiration and cognitive decline is assessed in different dimensions, and long-term risk aggravation warning can be generated through 30-day personal dynamic baseline and linear regression significance analysis. The present application solves the problems of data isolation, rough index and cognitive assessment blind area in the prior art, realizes non-invasive and accurate early warning of home health, and is suitable for home care monitoring of the elderly.

A system and method for detecting cognitive decline in a subject using a classification system for detecting cognitive decline in a subject based on speech samples.SOLUTION: The classification system is trained using speech data corresponding to audio recordings of speech from normal and cognitively impaired patients to generate an ensemble classifier that includes a plurality of component classifiers and an ensemble module. Each of the plurality of component classifiers is a machine learning classifier configured to generate a component output that identifies the sample data as corresponding to a normal patient or a cognitive patient. The machine learning classifier is generated based on a subset of the available features. The ensemble module receives the component outputs from all of the component classifiers and generates an ensemble output that identifies the sample data as corresponding to normal or cognitively impaired patients based on the component outputs.SELECTED DRAWING: None

The invention discloses a mild behavioral disorder cognitive decline prediction method based on multi-modal image fusion, and relates to the technical field of mild cognitive impairment prediction. According to the method, feature vectors of different modes are spliced to form a joint feature matrix, redundant information is eliminated through principal component analysis, and main variation components are reserved; inputting the feature set after dimension reduction into a prediction model based on machine learning, optimizing hyper-parameters through cross validation, and training a classifier so as to identify a cognitive decline risk mode of the patient with the mild behavioral disorder; multi-modal image data are received in real time through a standardized API interface, a prediction algorithm is automatically executed, and a report including individualized risk scores, confidence intervals, risk level classification and interpretability analysis is generated; the report is output in a structured format, so that a clinician can quickly refer to the report in the diagnosis process, meanwhile, the report is supported to be exported in a PDF or electronic health record format, and seamless integration with an existing medical information system is ensured.

The present invention relates to methods for treating, preventing or delaying disorders relating to cognition, such as cognitive decline, cognitive impairment or dementia. The present invention also relates to method for treating, preventing or delaying heart failure, such as heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).

The present disclosure relates to a method of improving cognitive function in a subject. The method includes implanting group-2 innate lymphoid cells (ILC2) in a cranium of a subject, where the ILC2 was treated with an ILC2 activator. The present disclosure further relates to a method including selecting a subject having aging-associated cognitive decline and administering to the subject an activator of innate lymphoid cell activity under conditions effective to promote innate lymphoid cell activity. The present disclosure further relates to a method of improving cognition in a subject. The method includes selecting a subject having aging-associated cognitive decline and administering to the subject a cytokine selected from the group consisting of IL-33, IL-5, IL-7, IL-25, and thymic stromal lymphopoietin.

The embodiment of the application relates to an AD course intelligent prediction method based on a time sequence neural network, comprising the following steps: collecting brain medical images and clinical cognitive evaluation data of a target object at multiple historical visit time points, recording actual interval lengths of each visit time point relative to the first visit, and obtaining a longitudinal multi-modal data set; extracting brain region image features and cognitive evaluation features at each time point, constituting a multi-modal feature vector, and arranging the multi-modal feature vector in time sequence to obtain a multi-modal time sequence feature sequence; obtaining a time sequence neural network model comprising a recurrent neural network layer and a time interval perception module, wherein the time interval perception module converts the actual interval length into a time decay coefficient to modulate hidden state updating; inputting the multi-modal time sequence feature sequence and the actual interval length into the model to generate a hidden state sequence; inputting the hidden state of the last time step into a fully connected output layer to output a cognitive decline rate value and / or a course stage category in a future preset time window.

New uses of a novel PPAR activity modulator for the prevention, amelioration or treatment of degenerative brain diseases are disclosed. More specifically, disclosed are a composition for the prevention, amelioration or treatment of degenerative brain diseases by using a PPAR active agent that binds to and activates all subtypes of PPAR of PPAR, and a composition for enhancing learning ability, improving memory, or ameliorating cognitive decline. Also, provided are a method for the prevention, amelioration or treatment of degenerative brain diseases by using the novel PPAR active agent, and a method for enhancing learning ability, improving memory or ameliorating cognitive decline.

Benzaza # imgabs0 # derivatives of formula (I), compositions comprising therapeutically effective amounts of these benzaza # imgabs1 # derivatives, and methods of using these derivatives or compositions in the treatment of cognitive impairment associated with central nervous system (CNS) disorders or associated with cognitive impairment risk factors. In particular, the present invention relates to the use of an alpha5-containing GABAA R agonist (e.g., an alpha5-containing GABAA R positive allosteric modulator) in the treatment of cognitive impairment associated with central nervous system (CNS) disorder or having a risk factor associated with cognitive impairment in a subject in need or at risk, the subjects include, but are not limited to, subjects having or at risk of age-related cognitive impairment, mild cognitive impairment (MCI), amnetic MCI (aMCI), age-related memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), proactive AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), or the like. Cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X disorder, Rett syndrome, compulsive behavior and substance addiction associated with cancer treatment. The present invention also relates to the use of [alpha] 5-containing GABAA R agonists (e.g., [alpha] 5-containing GABAA R positive allosteric modulators), as described herein, in the treatment of brain cancer, including brain tumors, e.g., myeloblastoma, and cognitive impairment associated therewith. # imgabs2 #

Provided herein are compounds, compositions, and methods for lowering expression levels of runt-related transcription factor 1 (RUNX1) in a cell, tissue or animal. Further provided are methods of improving memory and cognitive functioning in individuals with Down syndrome (DS) using an antisense compound targeted to a RUNX1 nucleic acid. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Further provided are methods of decreasing inflammation and slowing cognitive decline in individuals with dementia.